TIMEPIDIUM BROMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H22NOS2.Br
Molecular Weight	400.397
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Br-].COC1CC(C[N+](C)(C)C1)=C(C2=CC=CS2)C3=CC=CS3

InChI

InChIKey=QTSXMEPZSHLZFF-UHFFFAOYSA-M

InChI=1S/C17H22NOS2.BrH/c1-18(2)11-13(10-14(12-18)19-3)17(15-6-4-8-20-15)16-7-5-9-21-16;/h4-9,14H,10-12H2,1-3H3;1H/q+1;/p-1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7262709 | https://www.ncbi.nlm.nih.gov/pubmed/10374898

Timepidium bromide is a quaternary ammonium antimuscarinic used for the symptomatic treatment of visceral spasms. It is a muscarinic antagonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 169 Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	34.0 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	7.7 nM [Ki]
Muscarinic acetylcholine receptor M3 159 Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	31.0 nM [Ki]
Muscarinic acetylcholine receptor M4 86 Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	18.0 nM [Ki]
Muscarinic acetylcholine receptor M5 62 Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	11.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Visceral spasms 6 Sources: http://en.pharmacodia.com/web/drug/1_11398.html https://www.ncbi.nlm.nih.gov/pubmed/700518	Primary		Approved 8429	Sesden Approved Use Visceral spasms

PubMed

Title	Date	PubMed
Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide.	2002	12361147
Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis.	2004 Nov	15533228
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

Adult Dosage: 30mg x 3 times a day.

Route of Administration: Oral

In Vitro Use Guide

Timepidium inhibited dose-dependently the contraction of isolated guinea pig gallbladder evoked by stimulation at 5 Hz. The mean dose producing a 50 % decrease in the electrically induced contraction (ID50 value) was 2.4 x 10(-8) g/ml. Timepidium (10(-6) g/ml) also inhibited, for the most part, the contraction induced by stimulation at 30 Hz.

Name

Type

Language

TIMEPIDIUM BROMIDE

Official Name

English

3-(DI-2-THIENYLMETHYLENE)-5-METHOXY-1,1-DIMETHYL-PIPERIDINIUM BROMIDE

Systematic Name

English

Timepidium bromide [WHO-DD]

Common Name

English

TIMEPIDIUM BROMIDE [MART.]

Common Name

English

TIMEPIDIUM BROMIDE [MI]

Common Name

English

timepidium bromide [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03AB19